Search Results - "ABRAHAM, Prema"

Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-Related Macular Degeneration: PIER Study Year 2 by Abraham, Prema, Yue, Huibin, Wilson, Laura

“…Purpose To evaluate efficacy and safety of quarterly (and then monthly) ranibizumab during the 2-year P hase IIIb, multicenter, randomized, double-masked, sham…”
Get full text

Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-related Macular Degeneration: PIER Study Year 1 by Regillo, Carl D, Brown, David M, Abraham, Prema, Yue, Huibin, Ianchulev, Tsontcho, Schneider, Susan, Shams, Naveed

“…Purpose To evaluate the efficacy and safety of ranibizumab administered monthly for three months and then quarterly in patients with subfoveal choroidal…”
Get full text

Prospective evaluation of the incidence and risk factors for the development of RPE tears after high- and low-dose ranibizumab therapy by Sarraf, David, Chan, Clement, Rahimy, Ehsan, Abraham, Prema

“…To prospectively determine the incidence and risk factors for retinal pigment epithelial (RPE) tears in eyes with vascularized pigment epithelial detachments…”
Get full text

Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) Study by QUAN DONG NGUYEN, SHAH, Syed-Mahmood, HEIER, Jeffery S, DO, Diana V, LIM, Jennifer, BOYER, David, ABRAHAM, Prema, CAMPOCHIARO, Peter A

“…To compare ranibizumab with focal/grid laser or a combination of both in diabetic macular edema (DME). Prospective, randomized, interventional, multicenter…”
Get full text

Two-Year Outcomes of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) Study by Nguyen, Quan Dong, MD, MSc, Shah, Syed Mahmood, MBBS, Khwaja, Afsheen A., MD, Channa, Roomasa, MD, Hatef, Elham, MD, Do, Diana V., MD, Boyer, David, MD, Heier, Jeffery S., MD, Abraham, Prema, MD, Thach, Allen B., MD, Lit, Eugene S., MD, Foster, Bradley S., MD, Kruger, Erik, MD, Dugel, Pravin, MD, Chang, Thomas, MD, Das, Arup, MD, Ciulla, Thomas A., MD, Pollack, John S., MD, Lim, Jennifer I., MD, Eliot, Dean, MD, Campochiaro, Peter A., MD

“…Objectives To determine the long-term effects of ranibizumab (RBZ) in patients with diabetic macular edema (DME). Design Prospective, randomized,…”
Get full text

Primary Endpoint Results of a Phase II Study of Vascular Endothelial Growth Factor Trap-Eye in Wet Age-related Macular Degeneration by Brown, David M., MD, Heier, Jeffrey S., MD, Ciulla, Thomas, MD, Benz, Matthew, MD, Abraham, Prema, MD, Yancopoulos, George, MD, PhD, Stahl, Neil, PhD, Ingerman, Avner, MD, Vitti, Robert, MD, MBA, Berliner, Alyson J., MD, PhD, Yang, Ke, PhD, Nguyen, Quan Dong, MD, MSc

“…Objective To evaluate the biologic effects and safety of vascular endothelial growth factor (VEGF) Trap-Eye during a 12-week fixed-dosing period in patients…”
Get full text

Ranibizumab for Choroidal Neovascularization Secondary to Causes Other Than Age-Related Macular Degeneration: A Phase I Clinical Trial by Heier, Jeffrey S., MD, Brown, David, MD, Ciulla, Thomas, MD, Abraham, Prema, MD, Bankert, Joy M., RN, Chong, Sandy, BS, Daniel, Paul E., BS, Kim, Ivana K., MD

“…Purpose To investigate the safety and efficacy of ranibizumab for the treatment of choroidal neovascularization (CNV) secondary to causes other than…”
Get full text

Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration by Chan, Clement K, Meyer, Carsten H, Gross, Jeffrey G, Abraham, Prema, Nuthi, Asha S D, Kokame, Gregg T, Lin, Steven G, Rauser, Michael E, Kaiser, Peter K

“…To study retinal pigment epithelium (RPE) tears after off-label intravitreal bevacizumab (Avastin; Genentech, Inc., South San Francisco, CA) injection for…”
Get full text

Meticulous multimodal analysis of aflibercept therapy for submacular vascularized pigment epithelial detachment associated with neovascular AMD in a prospective case series, the EVEN study by Chan, Clement K., Sarraf, David, Abraham, Prema, Lalezary, Maziar, Lin, Steven G., Chen, Xuejing, Nittala, Muneeswar Gupta, Sadda, SriniVas

“…This prospective case series investigates the visual and anatomical outcomes including detailed volumetrics of eyes with vascularized pigment epithelial…”
Get full text

Intravitreal bevacizumab (avastin) in central retinal vein occlusion by Hsu, Jason, Kaiser, Richard S, Sivalingam, Arunan, Abraham, Prema, Fineman, Mitchell S, Samuel, Michael A, Vander, James F, Regillo, Carl D, Ho, Allen C

“…To describe the effects of intravitreal bevacizumab in eyes with macular edema resulting from central retinal vein occlusions (CRVO). Retrospective consecutive…”
Get full text

Clinical evaluation of the safety and efficacy of preservative-free triamcinolone (triesence [triamcinolone acetonide injectable suspension] 40 mg/ml) for visualization during pars plana vitrectomy by Dyer, David, Callanan, David, Bochow, Thomas, Abraham, Prema, Lambert, H Michael, Lee, S Young, Schneiderman, Todd, Potts, Susan L, Walker, Thomas M

“…To evaluate the safety and efficacy of preservative-free triamcinolone (TRIESENCE(R) suspension) for visualization during pars plana vitrectomy. This phase…”
Get full text

Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial by Liao, David S, Grossi, Federico V, El Mehdi, Delphine, Gerber, Monica R, Brown, David M, Heier, Jeffrey S, Wykoff, Charles C, Singerman, Lawrence J, Abraham, Prema, Grassmann, Felix, Nuernberg, Peter, Weber, Bernhard H F, Deschatelets, Pascal, Kim, Robert Y, Chung, Carol Y, Ribeiro, Ramiro M, Hamdani, Mohamed, Rosenfeld, Philip J, Boyer, David S, Slakter, Jason S, Francois, Cedric G

“…Geographic atrophy (GA), a late stage of age-related macular degeneration (AMD), is a major cause of blindness. Even while central visual acuity remains…”
Get full text

Effect of High-Dose Intravitreal Aflibercept, 8 mg, in Patients With Neovascular Age-Related Macular Degeneration: The Phase 2 CANDELA Randomized Clinical Trial by Wykoff, Charles C, Brown, David M, Reed, Kimberly, Berliner, Alyson J, Gerstenblith, Adam T, Breazna, Aurora, Abraham, Prema, Fein, Jordana G, Chu, Karen W, Clark, W Lloyd, Leal, Sergio, Schmelter, Thomas, Hirshberg, Boaz, Yancopoulos, George D, Vitti, Robert

“…Aflibercept, 8 mg, may have greater therapeutic benefits compared with aflibercept, 2 mg, in patients with neovascular age-related macular degeneration (nAMD),…”
Get more information

Treatment outcomes of conventional or high-dose ranibizumab for vascularized pigment epithelial detachment based on lesion subtypes by Chan, Clement K, Sarraf, David, Abraham, Prema

“…Introduction: A post hoc study was conducted to compare visual and anatomic outcomes of vascularized serous pigment epithelial detachment (Group 1) with…”
Get full text

Post-hoc analysis of single nucleotide polymorphism profile for eyes with vascularized pigment epithelial detachment due to ARMD by Lee, Daniel, Chan, Clement K, Abraham, Prema, Sarraf, David

“…This post-hoc case-control study compares single nucleotide polymorphism (SNP) profile of eyes with vascularized pigment epithelial detachment (vPED) due to…”
Get full text

Single nucleotide polymorphism profiles associated with three common phenotypes of advanced age‐related macular degeneration by Ng, Caleb C., Chan, Clement K., Abraham, Prema, Hafner, Andre D.

Get full text

TYPE 1 VERSUS TYPE 3 NEOVASCULARIZATION IN PIGMENT EPITHELIAL DETACHMENTS ASSOCIATED WITH AGE-RELATED MACULAR DEGENERATION AFTER ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY: A Prospective Study by Chen, Xuejing, Al-Sheikh, Mayss, Chan, Clement K, Hariri, Amir H, Abraham, Prema, Lalezary, Maziar, Lin, Steven G, Sadda, SriniVas, Sarraf, David

“…To evaluate the response to aflibercept therapy for Type 1 and Type 3 neovascularization in pigment epithelial detachments associated with treatment-naive,…”
Get full text

Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration by Liao, David S., Grossi, Federico V., El Mehdi, Delphine, Gerber, Monica R., Brown, David M., Heier, Jeffrey S., Wykoff, Charles C., Singerman, Lawrence J., Abraham, Prema, Grassmann, Felix, Nuernberg, Peter, Weber, Bernhard H.F., Deschatelets, Pascal, Kim, Robert Y., Chung, Carol Y., Ribeiro, Ramiro M., Hamdani, Mohamed, Rosenfeld, Philip J., Boyer, David S., Slakter, Jason S., Francois, Cedric G.

“…Geographic atrophy (GA), a late stage of age-related macular degeneration (AMD), is a major cause of blindness. Even while central visual acuity remains…”
Get full text

Twenty-four–Month Outcomes of the Ranibizumab for Edema of the Macula in Diabetes – Protocol 3 with High Dose (READ-3) Study by Sepah, Yasir J., MBBS, Sadiq, Mohammad Ali, MBBS, Boyer, David, MD, Callanan, David, MD, Gallemore, Ron, MD, Bennett, Michael, MD, Marcus, Dennis, MD, Halperin, Lawrence, MD, Hassan, Muhammad, MBBS, Campochiaro, Peter A., MD, Nguyen, Quan Dong, MD, MSc, Do, Diana V., MD

“…Purpose To compare 2.0 mg ranibizumab (RBZ) injections with 0.5 mg RBZ for eyes with center-involved diabetic macular edema (DME). Design Randomized,…”
Get full text

Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy by Aiello, Lloyd Paul, Davis, Matthew D, Girach, Aniz, Kles, Keri A, Milton, Roy C, Sheetz, Matthew J, Vignati, Louis, Zhi, Xin Eric

“…To evaluate the effect of ruboxistaurin, an orally administered protein kinase C beta (PKC beta) isozyme-selective inhibitor, on vision loss in patients with…”
Get more information